Type 2 Diabetes

The FDA has announced the approval of semaglutide 2.4 mg (Wegovy) for chronic weight management in patients with obesity or overweight—the first drug to receive such an approval from the FDA in more than half a decade.

The indication makes the Novo Nordisk product the first weekly injection GLP-1 agonist approved for managing overweight and obesity.

A look at more than 2800 older patients with type 1 diabetes indicates experiencing severe glycemic events was linked to an increased risk of developing dementia.

A retrospective look at patients who initated real-time CGM versus noninitiators indicates CGM use resulted in significant reductions in HbA1c and also reduced the number of outpatient and telephone visits among patients with type 1 diabetes and type 2 diabetes.

A trial of more than 150 patients with type 2 diabetes using basal insulin without prandial insulin suggests CGM use among these patients could lower HbA1c and improve time in target range compared to traditional blood glucose monitoring.

Analysis of claims data from the Symphony database offers clinicians greater insight into the impact of diabetes, both type 1 and type 2, on thyroid eye disease in US patients.

A systematic review and meta-analysis presented at AACE 2021 shed light on risk factors associated with increased odds of developing peripheral artery disease among patients with type 2 diabetes.

A systematic review and meta-analysis presented at AACE 2021 sheds light on risk factors associated with increased odds of developing peripheral artery disease among patients with type 2 diabetes.

Despite the investigators' hypothesis, implementing use of CGM at hospital discharge did not reduce risk of emergency department visits or rehospitalizations among patients with uncontrolled type 2 diabetes.

A retrospective analysis of EHR data suggests use of CGM or visits from a diabetes educator or nutritionist were associated with a decrease in gaps between receiving care at a pediatric endocrinology clinic and an adult clinic among patients transitioning from pediatric to adult diabetes.

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 in support of teplizumab for delaying clinical type 1 diabetes in a meeting on May 27.

The EMDAC voted 10-7 to support the benefit-risks of teplizumab for delaying clinical type 1 diabetes.

Data from a retrospective review of patients with type 2 diabetes and heart failure at a diabetes center in Maryland details trends in prescribing and discontinuation in a real-world setting over a 5-year period.

A systematic review and meta-analysis of a dozen trials assessing the MiniMed 670G system provides insight into the effects of the hybrid closed-loop system on A1c and time in range among patients with type 1 diabetes.

A 23-year study suggests presence of autoantibodies could aid clinicians in predicting the risk of developing type 1 diabetes among women with gestational diabetes.

Analysis of the UK Biobank cohort details a graded increase in risk of cardiovascular and renal events across the glycemic spectrum, including among patients with prediabetes.

Analysis of data from the FIDELIO-DKD trial suggests use of finerenone was associated with a nearly 30% reduction in new-onset atrial fibrillation among patients within the phase 3 trial.

An analysis of 9 trials examining SGLT2 inhibitors in patients with heart failure provides insight into the effects of the agents across the spectrum of heart failure, including those with decreased eGFR and preserved ejection fraction.

An analysis of FIDELIO-DKD indicates use of finerenone was associated with significant reductions in risk of new-onset atrial fibrillation in patients with type 2 diabetes and chronic kidney disease.

While the trial failed to meet its primary endpoint, results of DARE-19 provide valuable insight into the effects of SGLT2 inhibition and use of dapagliflozin in patients with COVID-19.

An ACC.21 study assessing the risk of adverse cardiovascular and renal outcomes found a graded increase in risk across the entire glycemic spectrum, including prediabetic levels.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

Research from ARVO 2021 details the complexities and current challenges faced when attempting to address the burden of diabetic eye disease while the number of patients with diabetes in the US continues to balloon.

A new phase 1 trial presented at ECO 2021 demonstrates the impact of semaglutide on appetite and body weight in patients with obesity, indicating use of the GLP-1 RA reduced energy intake 35% and resulted in a nearly 10% reduction in body weight over 20 weeks.

An analysis of nearly 2 million patients suggests an increased BMI around the age of 18 was linked to a graded increase in the risk of ischemic stroke in midlife, regardless of diabetes status.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.

An analysis of data from more than 250k kidney transplant patients details the increased risk of mortality and graft failure according to diabetes status among these patients.

Bigfoot Medical announced the FDA granted 510(k) clearance to the Bigfoot Unity System for use in patients with type 1 or type 2 diabetes aged 12 years and older.

The smart pen cap system is associated with real-time hypoglycemia alerts and insulin dose recommendations.

An analysis presented ahead of ACC.21 details the increased risk of MACE associated with prediabetes, suggesting patients were at nearly twice the risk of experiencing a major cardiovascular event.